Mirati Therapeutics (MRTX) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Mirati Therapeutics (MRTXResearch Report) today and set a price target of $117.00. The company’s shares closed last Monday at $104.78, close to its 52-week high of $111.99.

According to TipRanks.com, White is a 5-star analyst with an average return of 15.5% and a 51.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Currently, the analyst consensus on Mirati Therapeutics is a Moderate Buy with an average price target of $106.22, implying a 7.5% upside from current levels. In a report issued on October 29, JonesTrading also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $111.99 and a one-year low of $34.39. Currently, Mirati Therapeutics has an average volume of 646.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat.